Halofuginone, a Specific Inhibitor of Collagen Type 1 Synthesis, Ameliorates Oxidant Colonic Damage in Rats with Experimental Colitis

被引：0
作者：
Berna Karakoyun
Meral Yüksel
Feriha Ercan
Emine Salva
Işıl Işık
Berrak Ç. Yeğen
机构：
[1] Marmara University,Health Sciences Faculty, Department of Nursing
[2] Marmara University,Vocational School of Health Related Professions, Department of Medical Laboratory
[3] Marmara University,School of Medicine, Departments of Histology and Embriology
[4] Marmara University,Vocational School of Health Related Professions, Department of Pathology
[5] Marmara University,School of Medicine, Department of Physiology
来源：
Digestive Diseases and Sciences | 2010年 / 55卷
关键词：
Halofuginone; Colitis; Trinitrobenzene sulfonic acid (TNBS); Oxidant damage; Collagen;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
To evaluate the effect of halofuginone on trinitrobenzene sulfonic acid (TNBS)-induced colonic injury, rats were given halofuginone (40 μg/kg, intraperitoneally) or saline 1 h before the induction of colitis, and the injections were continued twice daily for 3 days until they were decapitated. High macroscopic and microscopic damage scores, elevated colonic wet weights, colonic myeloperoxidase activity, malondialdehyde and tissue collagen level, and luminol chemiluminescence values, and marked reduction in glutathione level of the saline-treated colitis group were all reversed by treatment with halofuginone. In conclusion, halofuginone exerts beneficial effects in TNBS-induced colonic inflammation in rats. The anti-inflammatory effects of halofuginone appear to involve suppression of neutrophil accumulation, preservation of endogenous glutathione, and inhibition of reactive oxidant generation. Halofuginone also shows antifibrotic effect via inhibition of tissue collagen production. The present data encourage possible use of the antifibrotic halofuginone as an anti-inflammatory agent in improving oxidative injury in colitis.
引用
收藏
页码：607 / 616
页数：9
相关论文
共 215 条
  • [1] Granot I(1991)Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone Poult Sci 70 1559-1563
  • [2] Bartov I(1993)Halofuginone: An inhibitor of collagen type I synthesis Biochim Biophys Acta 1156 107-112
  • [3] Plavnik I(1996)Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: Effect of halofuginone Biochem Pharmacol 52 1057-1063
  • [4] Wax E(1997)Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone Arterioscler Thromb Vasc Biol 17 194-202
  • [5] Hurwitz S(1998)Halofuginone: A novel antifibrotic therapy Gen Pharmacol 30 445-450
  • [6] Pines M(1996)Reduction in pulmonary fibrosis in vivo by halofuginone Am J Respir Crit Care Med 154 1082-1086
  • [7] Granot I(2008)The effect of halofuginone, a specific inhibitor of collagen type 1 synthesis, in the prevention of pancreatic fibrosis in an experimental model of severe hyperstimulation and obstruction pancreatitis J Surg Res 148 7-12
  • [8] Halevy O(1997)Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis J Hepatol 27 391-398
  • [9] Hurwitz S(2001)Halofuginone to prevent and treat thioacetamide-induced liver fibrosisin rats Hepatology 33 379-386
  • [10] Pines M(2007)Halofuginone reduces the occurrence of renal fibrosis in 5/6 nephrectomized rats Isr Med Assoc J 9 30-34
12345678910